Loading…
Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis
Pancreatic ductal adenocarcinoma (PDAC) diagnosis can be difficult in a chronic pancreatitis (CP) background, especially in its mass forming presentation. We aimed to assess the accuracy of glypican-1-positive circulating exosomes (GPC1+crExos) to distinguish PDAC from CP versus the state-of-the-art...
Saved in:
| Published in: | Digestive and liver disease 2022-07, Vol.54 (7), p.871-877 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c396t-56add0e33178a65c8d2adbb737971e1ae0f79d249c07e40f08588d8b07ecabf23 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c396t-56add0e33178a65c8d2adbb737971e1ae0f79d249c07e40f08588d8b07ecabf23 |
| container_end_page | 877 |
| container_issue | 7 |
| container_start_page | 871 |
| container_title | Digestive and liver disease |
| container_volume | 54 |
| creator | Moutinho-Ribeiro, P. Adem, B. Batista, I. Silva, M. Silva, S. Ruivo, C.F. Morais, R. Peixoto, A. Coelho, R. Costa-Moreira, P. Lopes, S. Vilas-Boas, F. Durães, C. Lopes, J. Barroca, H. Carneiro, F. Melo, S.A. Macedo, G. |
| description | Pancreatic ductal adenocarcinoma (PDAC) diagnosis can be difficult in a chronic pancreatitis (CP) background, especially in its mass forming presentation. We aimed to assess the accuracy of glypican-1-positive circulating exosomes (GPC1+crExos) to distinguish PDAC from CP versus the state-of-the-art CA 19–9 biomarker.
This was a unicentric prospective cohort. Endoscopic ultrasound with fine-needle aspiration or biopsy and blood tests (GPC1+crExos and serum CA 19–9) were performed.
The cohort comprised 60 PDAC and 29 CP (7 of which mass forming - MF) patients. Median levels of GPC1+crExos were significantly higher in PDAC (99.7%) versus CP (28.4%; p |
| doi_str_mv | 10.1016/j.dld.2021.10.012 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2604463022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1590865821008422</els_id><sourcerecordid>2604463022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-56add0e33178a65c8d2adbb737971e1ae0f79d249c07e40f08588d8b07ecabf23</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMojo7-ADfSpZvWJG3TFFcyjA8YcKM7IaTJrWZokzFpxfn3psw4S1f3wXcOnIPQFcEZwYTdrjPd6YxiSuKdYUKP0BnhFU_zktHjuJc1Tjkr-Qydh7DGEWQlPkWzvOBFxKsz9L78ccH1sks-uu3GKGlTkmgTlDe9sXKAkGykVR7kYFSiRzVEVGqwTkmvjI3SpPWuT9SndzYiB3ow4QKdtLILcLmfc_T2sHxdPKWrl8fnxf0qVXnNhrRkUmsMeU4qLlmpuKZSN02VV3VFgEjAbVVrWtQKV1DgFvOSc82beCnZtDSfo5ud78a7rxHCIPqYALpOWnBjEJThomA5phNKdqjyLgQPrdjEpNJvBcFiKlWsRSxVTKVOr9hS1Fzv7cemB31Q_LUYgbsdADHktwEvgjJgFWjjQQ1CO_OP_S9rwoj1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2604463022</pqid></control><display><type>article</type><title>Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis</title><source>ScienceDirect Freedom Collection</source><creator>Moutinho-Ribeiro, P. ; Adem, B. ; Batista, I. ; Silva, M. ; Silva, S. ; Ruivo, C.F. ; Morais, R. ; Peixoto, A. ; Coelho, R. ; Costa-Moreira, P. ; Lopes, S. ; Vilas-Boas, F. ; Durães, C. ; Lopes, J. ; Barroca, H. ; Carneiro, F. ; Melo, S.A. ; Macedo, G.</creator><creatorcontrib>Moutinho-Ribeiro, P. ; Adem, B. ; Batista, I. ; Silva, M. ; Silva, S. ; Ruivo, C.F. ; Morais, R. ; Peixoto, A. ; Coelho, R. ; Costa-Moreira, P. ; Lopes, S. ; Vilas-Boas, F. ; Durães, C. ; Lopes, J. ; Barroca, H. ; Carneiro, F. ; Melo, S.A. ; Macedo, G.</creatorcontrib><description>Pancreatic ductal adenocarcinoma (PDAC) diagnosis can be difficult in a chronic pancreatitis (CP) background, especially in its mass forming presentation. We aimed to assess the accuracy of glypican-1-positive circulating exosomes (GPC1+crExos) to distinguish PDAC from CP versus the state-of-the-art CA 19–9 biomarker.
This was a unicentric prospective cohort. Endoscopic ultrasound with fine-needle aspiration or biopsy and blood tests (GPC1+crExos and serum CA 19–9) were performed.
The cohort comprised 60 PDAC and 29 CP (7 of which mass forming - MF) patients. Median levels of GPC1+crExos were significantly higher in PDAC (99.7%) versus CP (28.4%; p<0.0001) with an AUROC of 0.96 with 98.3% sensitivity and 86.2% specificity for a cut-off of 45.0% (p<0.0001); this outperforms CA 19–9 AUROC of 0.82 with 78.3% sensitivity and 65.5% specificity at a cut-off of 37 U/mL (p<0.0001). The superiority of% GPC1+crExos over CA 19–99 in differentiating PDAC from CP was observed in both early (stage I) and advanced tumors (stages II-IV).
Levels of GPC1+crExos coupled to beads enable differential diagnosis between PDAC and CP including its mass-forming presentation.</description><identifier>ISSN: 1590-8658</identifier><identifier>EISSN: 1878-3562</identifier><identifier>DOI: 10.1016/j.dld.2021.10.012</identifier><identifier>PMID: 34840127</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Biomarkers, Tumor ; CA 19.9 ; CA-19-9 Antigen ; Carcinoma, Pancreatic Ductal - diagnosis ; Carcinoma, Pancreatic Ductal - pathology ; Chronic pancreatitis ; Diagnosis, Differential ; Endoscopic ultrasound ; Glypican-1 ; Glypicans ; Humans ; Pancreatic ductal adenocarcinoma ; Pancreatic Neoplasms ; Pancreatic Neoplasms - diagnosis ; Pancreatic Neoplasms - pathology ; Pancreatitis, Chronic - diagnosis ; Prospective Studies</subject><ispartof>Digestive and liver disease, 2022-07, Vol.54 (7), p.871-877</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-56add0e33178a65c8d2adbb737971e1ae0f79d249c07e40f08588d8b07ecabf23</citedby><cites>FETCH-LOGICAL-c396t-56add0e33178a65c8d2adbb737971e1ae0f79d249c07e40f08588d8b07ecabf23</cites><orcidid>0000-0002-9387-9872</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34840127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moutinho-Ribeiro, P.</creatorcontrib><creatorcontrib>Adem, B.</creatorcontrib><creatorcontrib>Batista, I.</creatorcontrib><creatorcontrib>Silva, M.</creatorcontrib><creatorcontrib>Silva, S.</creatorcontrib><creatorcontrib>Ruivo, C.F.</creatorcontrib><creatorcontrib>Morais, R.</creatorcontrib><creatorcontrib>Peixoto, A.</creatorcontrib><creatorcontrib>Coelho, R.</creatorcontrib><creatorcontrib>Costa-Moreira, P.</creatorcontrib><creatorcontrib>Lopes, S.</creatorcontrib><creatorcontrib>Vilas-Boas, F.</creatorcontrib><creatorcontrib>Durães, C.</creatorcontrib><creatorcontrib>Lopes, J.</creatorcontrib><creatorcontrib>Barroca, H.</creatorcontrib><creatorcontrib>Carneiro, F.</creatorcontrib><creatorcontrib>Melo, S.A.</creatorcontrib><creatorcontrib>Macedo, G.</creatorcontrib><title>Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis</title><title>Digestive and liver disease</title><addtitle>Dig Liver Dis</addtitle><description>Pancreatic ductal adenocarcinoma (PDAC) diagnosis can be difficult in a chronic pancreatitis (CP) background, especially in its mass forming presentation. We aimed to assess the accuracy of glypican-1-positive circulating exosomes (GPC1+crExos) to distinguish PDAC from CP versus the state-of-the-art CA 19–9 biomarker.
This was a unicentric prospective cohort. Endoscopic ultrasound with fine-needle aspiration or biopsy and blood tests (GPC1+crExos and serum CA 19–9) were performed.
The cohort comprised 60 PDAC and 29 CP (7 of which mass forming - MF) patients. Median levels of GPC1+crExos were significantly higher in PDAC (99.7%) versus CP (28.4%; p<0.0001) with an AUROC of 0.96 with 98.3% sensitivity and 86.2% specificity for a cut-off of 45.0% (p<0.0001); this outperforms CA 19–9 AUROC of 0.82 with 78.3% sensitivity and 65.5% specificity at a cut-off of 37 U/mL (p<0.0001). The superiority of% GPC1+crExos over CA 19–99 in differentiating PDAC from CP was observed in both early (stage I) and advanced tumors (stages II-IV).
Levels of GPC1+crExos coupled to beads enable differential diagnosis between PDAC and CP including its mass-forming presentation.</description><subject>Biomarkers, Tumor</subject><subject>CA 19.9</subject><subject>CA-19-9 Antigen</subject><subject>Carcinoma, Pancreatic Ductal - diagnosis</subject><subject>Carcinoma, Pancreatic Ductal - pathology</subject><subject>Chronic pancreatitis</subject><subject>Diagnosis, Differential</subject><subject>Endoscopic ultrasound</subject><subject>Glypican-1</subject><subject>Glypicans</subject><subject>Humans</subject><subject>Pancreatic ductal adenocarcinoma</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - diagnosis</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatitis, Chronic - diagnosis</subject><subject>Prospective Studies</subject><issn>1590-8658</issn><issn>1878-3562</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLxDAUhYMojo7-ADfSpZvWJG3TFFcyjA8YcKM7IaTJrWZokzFpxfn3psw4S1f3wXcOnIPQFcEZwYTdrjPd6YxiSuKdYUKP0BnhFU_zktHjuJc1Tjkr-Qydh7DGEWQlPkWzvOBFxKsz9L78ccH1sks-uu3GKGlTkmgTlDe9sXKAkGykVR7kYFSiRzVEVGqwTkmvjI3SpPWuT9SndzYiB3ow4QKdtLILcLmfc_T2sHxdPKWrl8fnxf0qVXnNhrRkUmsMeU4qLlmpuKZSN02VV3VFgEjAbVVrWtQKV1DgFvOSc82beCnZtDSfo5ud78a7rxHCIPqYALpOWnBjEJThomA5phNKdqjyLgQPrdjEpNJvBcFiKlWsRSxVTKVOr9hS1Fzv7cemB31Q_LUYgbsdADHktwEvgjJgFWjjQQ1CO_OP_S9rwoj1</recordid><startdate>202207</startdate><enddate>202207</enddate><creator>Moutinho-Ribeiro, P.</creator><creator>Adem, B.</creator><creator>Batista, I.</creator><creator>Silva, M.</creator><creator>Silva, S.</creator><creator>Ruivo, C.F.</creator><creator>Morais, R.</creator><creator>Peixoto, A.</creator><creator>Coelho, R.</creator><creator>Costa-Moreira, P.</creator><creator>Lopes, S.</creator><creator>Vilas-Boas, F.</creator><creator>Durães, C.</creator><creator>Lopes, J.</creator><creator>Barroca, H.</creator><creator>Carneiro, F.</creator><creator>Melo, S.A.</creator><creator>Macedo, G.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9387-9872</orcidid></search><sort><creationdate>202207</creationdate><title>Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis</title><author>Moutinho-Ribeiro, P. ; Adem, B. ; Batista, I. ; Silva, M. ; Silva, S. ; Ruivo, C.F. ; Morais, R. ; Peixoto, A. ; Coelho, R. ; Costa-Moreira, P. ; Lopes, S. ; Vilas-Boas, F. ; Durães, C. ; Lopes, J. ; Barroca, H. ; Carneiro, F. ; Melo, S.A. ; Macedo, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-56add0e33178a65c8d2adbb737971e1ae0f79d249c07e40f08588d8b07ecabf23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers, Tumor</topic><topic>CA 19.9</topic><topic>CA-19-9 Antigen</topic><topic>Carcinoma, Pancreatic Ductal - diagnosis</topic><topic>Carcinoma, Pancreatic Ductal - pathology</topic><topic>Chronic pancreatitis</topic><topic>Diagnosis, Differential</topic><topic>Endoscopic ultrasound</topic><topic>Glypican-1</topic><topic>Glypicans</topic><topic>Humans</topic><topic>Pancreatic ductal adenocarcinoma</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - diagnosis</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatitis, Chronic - diagnosis</topic><topic>Prospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moutinho-Ribeiro, P.</creatorcontrib><creatorcontrib>Adem, B.</creatorcontrib><creatorcontrib>Batista, I.</creatorcontrib><creatorcontrib>Silva, M.</creatorcontrib><creatorcontrib>Silva, S.</creatorcontrib><creatorcontrib>Ruivo, C.F.</creatorcontrib><creatorcontrib>Morais, R.</creatorcontrib><creatorcontrib>Peixoto, A.</creatorcontrib><creatorcontrib>Coelho, R.</creatorcontrib><creatorcontrib>Costa-Moreira, P.</creatorcontrib><creatorcontrib>Lopes, S.</creatorcontrib><creatorcontrib>Vilas-Boas, F.</creatorcontrib><creatorcontrib>Durães, C.</creatorcontrib><creatorcontrib>Lopes, J.</creatorcontrib><creatorcontrib>Barroca, H.</creatorcontrib><creatorcontrib>Carneiro, F.</creatorcontrib><creatorcontrib>Melo, S.A.</creatorcontrib><creatorcontrib>Macedo, G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive and liver disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moutinho-Ribeiro, P.</au><au>Adem, B.</au><au>Batista, I.</au><au>Silva, M.</au><au>Silva, S.</au><au>Ruivo, C.F.</au><au>Morais, R.</au><au>Peixoto, A.</au><au>Coelho, R.</au><au>Costa-Moreira, P.</au><au>Lopes, S.</au><au>Vilas-Boas, F.</au><au>Durães, C.</au><au>Lopes, J.</au><au>Barroca, H.</au><au>Carneiro, F.</au><au>Melo, S.A.</au><au>Macedo, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis</atitle><jtitle>Digestive and liver disease</jtitle><addtitle>Dig Liver Dis</addtitle><date>2022-07</date><risdate>2022</risdate><volume>54</volume><issue>7</issue><spage>871</spage><epage>877</epage><pages>871-877</pages><issn>1590-8658</issn><eissn>1878-3562</eissn><abstract>Pancreatic ductal adenocarcinoma (PDAC) diagnosis can be difficult in a chronic pancreatitis (CP) background, especially in its mass forming presentation. We aimed to assess the accuracy of glypican-1-positive circulating exosomes (GPC1+crExos) to distinguish PDAC from CP versus the state-of-the-art CA 19–9 biomarker.
This was a unicentric prospective cohort. Endoscopic ultrasound with fine-needle aspiration or biopsy and blood tests (GPC1+crExos and serum CA 19–9) were performed.
The cohort comprised 60 PDAC and 29 CP (7 of which mass forming - MF) patients. Median levels of GPC1+crExos were significantly higher in PDAC (99.7%) versus CP (28.4%; p<0.0001) with an AUROC of 0.96 with 98.3% sensitivity and 86.2% specificity for a cut-off of 45.0% (p<0.0001); this outperforms CA 19–9 AUROC of 0.82 with 78.3% sensitivity and 65.5% specificity at a cut-off of 37 U/mL (p<0.0001). The superiority of% GPC1+crExos over CA 19–99 in differentiating PDAC from CP was observed in both early (stage I) and advanced tumors (stages II-IV).
Levels of GPC1+crExos coupled to beads enable differential diagnosis between PDAC and CP including its mass-forming presentation.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>34840127</pmid><doi>10.1016/j.dld.2021.10.012</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-9387-9872</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1590-8658 |
| ispartof | Digestive and liver disease, 2022-07, Vol.54 (7), p.871-877 |
| issn | 1590-8658 1878-3562 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2604463022 |
| source | ScienceDirect Freedom Collection |
| subjects | Biomarkers, Tumor CA 19.9 CA-19-9 Antigen Carcinoma, Pancreatic Ductal - diagnosis Carcinoma, Pancreatic Ductal - pathology Chronic pancreatitis Diagnosis, Differential Endoscopic ultrasound Glypican-1 Glypicans Humans Pancreatic ductal adenocarcinoma Pancreatic Neoplasms Pancreatic Neoplasms - diagnosis Pancreatic Neoplasms - pathology Pancreatitis, Chronic - diagnosis Prospective Studies |
| title | Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T23%3A36%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exosomal%20glypican-1%20discriminates%20pancreatic%20ductal%20adenocarcinoma%20from%20chronic%20pancreatitis&rft.jtitle=Digestive%20and%20liver%20disease&rft.au=Moutinho-Ribeiro,%20P.&rft.date=2022-07&rft.volume=54&rft.issue=7&rft.spage=871&rft.epage=877&rft.pages=871-877&rft.issn=1590-8658&rft.eissn=1878-3562&rft_id=info:doi/10.1016/j.dld.2021.10.012&rft_dat=%3Cproquest_cross%3E2604463022%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c396t-56add0e33178a65c8d2adbb737971e1ae0f79d249c07e40f08588d8b07ecabf23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2604463022&rft_id=info:pmid/34840127&rfr_iscdi=true |